Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation

• Status: Unknown status
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

All the studies, demonstrating improved oocyte maturity and high pregnancy rate with the dual trigger are all retrospective. The investigators therefore aim to perform a prospective randomized controlled study in normal responders, comparing cycles triggered with hCG to those triggered with hCG+GnRH agonist.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mount Sinai Hospital, Canada
• Treatments: Buserelin; Chorionic Gonadotropin; Deslorelin

Criteria

Inclusion Criteria:

• Women during one of their first 3 IVF cycle attempts

• Women between the ages of 18-42.

• BMI (body mass index) of 18-35.

• AMH (Anti mullerian hormone) > 1 ng/ml

• FSH˂ 20 IU/L.

• Informed consent.

Exclusion Criteria:

• Women with low ovarian response

• Previous enrollment in this study.

• AFC>20

• E2 above 15,000 pmol/l at the trigger day.

• hypersensitive to Suprefact/Pregny/gonal F/Purigon/Menopur/progesterone, and/or their ingredients/components of the formulation

• primary ovarian failure

• pregnancy and breast-feeding

• active blood clots

• undiagnosed uterine or genital bleeding

• endometriosis

• uncontrolled hypertension;

• uncontrolled diabetes

• abnormal liver and kidney functions

• abnormal ECG, e.g. QT prolongation and torsades de pointes

• cancers/tumors, e.g. pituitary adenomas, ovarian cysts, etc.

• HIV, HBV and HCV infections

• low bone mineral density (BMD) and an increased risk of bone fracture, such as chronic alcohol and/or tobacco use, presumed or strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids

• suicidal tendency, history or disposition to seizures, state of confusion, clinically relevant psychiatric disorders, and brain lesions

• Use of an investigational drug or participation in an investigational study within 30 days prior to this study.